More Argent Biopharma Ltd news
Argent Biopharma LtdASX: RGT

Cognicann Clinical Trial Results

Jun 6, 2022 at 5:44 AM EDT · Issued by Argent Biopharma Ltd

Filed with ASX · Jun 6, 2022 at 5:44 AM EDT

On 6ix: 6ix.com/news/cognicann-clinical-trial-results

Argent Biopharma Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Argent Biopharma Ltd on 6ix

Story so far

  • Artemic eu sale approval and clinical trial updateSep 16, 2021
  • 1St patient recruited into cimetra phase 3 clinical trialJul 13, 2021
  • Ethics Committee Approval Granted Phase III Clinical TrialMar 23, 2021

Earlier from Argent Biopharma

  • Response to ASX Aware QueryMay 17, 2022
  • Patent Granted for CannEpiL SNEDDSMay 10, 2022
  • March 2022 Quarterly Activity and Cash Flow ReportsApr 29, 2022
  • Patent Granted for CimetrAApr 21, 2022
  • Sciensus Rare EU & UK Sales and Distribution AgreementApr 5, 2022

Later from Argent Biopharma

  • Glioblastoma pre-clinical trial resultsJun 16, 2022
  • CimetrA anti-inflammatory pre-clinical study resultsJun 27, 2022
  • Approvals received for South African CimetrA Clinical TrialJul 8, 2022
  • Long COVID Study Results for ArtemiC SupportJul 14, 2022
  • June Quarter Activities and Cash Flow ReportJul 24, 2022
All Argent Biopharma news releases↗

Follow Argent Biopharma into a list and get an email when it puts out news.

Follow Argent Biopharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer